Ultragenyx Pharmaceutical (RARE) Downgraded by BidaskClub

BidaskClub lowered shares of Ultragenyx Pharmaceutical (NASDAQ:RARE) from a hold rating to a sell rating in a research report released on Tuesday morning.

Other research analysts have also recently issued research reports about the company. Canaccord Genuity reaffirmed a buy rating on shares of Ultragenyx Pharmaceutical in a research report on Tuesday, September 12th. Stifel Nicolaus reaffirmed a buy rating and set a $85.00 price target (down previously from $95.00) on shares of Ultragenyx Pharmaceutical in a research report on Wednesday, August 23rd. J P Morgan Chase & Co set a $76.00 price target on Ultragenyx Pharmaceutical and gave the company a buy rating in a research report on Wednesday, August 23rd. Robert W. Baird reaffirmed a buy rating on shares of Ultragenyx Pharmaceutical in a research report on Tuesday, September 19th. Finally, Cowen reaffirmed a buy rating on shares of Ultragenyx Pharmaceutical in a research report on Wednesday, November 15th. One analyst has rated the stock with a sell rating, nine have assigned a hold rating and ten have issued a buy rating to the company’s stock. The stock currently has a consensus rating of Hold and an average price target of $72.40.

Shares of Ultragenyx Pharmaceutical (RARE) traded down $1.17 during trading hours on Tuesday, reaching $44.02. The company’s stock had a trading volume of 313,600 shares, compared to its average volume of 438,466. Ultragenyx Pharmaceutical has a 52-week low of $43.38 and a 52-week high of $91.35.

Ultragenyx Pharmaceutical (NASDAQ:RARE) last announced its quarterly earnings data on Thursday, November 2nd. The biopharmaceutical company reported ($1.87) earnings per share (EPS) for the quarter, meeting analysts’ consensus estimates of ($1.87). The business had revenue of $0.20 million during the quarter, compared to the consensus estimate of $0.02 million. During the same quarter last year, the company earned ($1.64) EPS. The firm’s revenue for the quarter was up 81.8% compared to the same quarter last year. equities research analysts expect that Ultragenyx Pharmaceutical will post -7.27 earnings per share for the current fiscal year.

A number of institutional investors and hedge funds have recently modified their holdings of the stock. Ameritas Investment Partners Inc. lifted its holdings in Ultragenyx Pharmaceutical by 7.7% during the 2nd quarter. Ameritas Investment Partners Inc. now owns 3,474 shares of the biopharmaceutical company’s stock worth $216,000 after purchasing an additional 248 shares in the last quarter. Tocqueville Asset Management L.P. lifted its holdings in Ultragenyx Pharmaceutical by 8.0% during the 2nd quarter. Tocqueville Asset Management L.P. now owns 3,375 shares of the biopharmaceutical company’s stock worth $210,000 after purchasing an additional 250 shares in the last quarter. Aperio Group LLC lifted its holdings in Ultragenyx Pharmaceutical by 8.4% during the 2nd quarter. Aperio Group LLC now owns 3,851 shares of the biopharmaceutical company’s stock worth $239,000 after purchasing an additional 299 shares in the last quarter. Amalgamated Bank raised its holdings in shares of Ultragenyx Pharmaceutical by 7.6% in the 2nd quarter. Amalgamated Bank now owns 4,980 shares of the biopharmaceutical company’s stock valued at $309,000 after acquiring an additional 352 shares in the last quarter. Finally, Pacer Advisors Inc. raised its holdings in shares of Ultragenyx Pharmaceutical by 12.0% in the 2nd quarter. Pacer Advisors Inc. now owns 3,402 shares of the biopharmaceutical company’s stock valued at $211,000 after acquiring an additional 365 shares in the last quarter. 94.13% of the stock is currently owned by institutional investors and hedge funds.

COPYRIGHT VIOLATION WARNING: “Ultragenyx Pharmaceutical (RARE) Downgraded by BidaskClub” was reported by The Ledger Gazette and is the property of of The Ledger Gazette. If you are viewing this report on another site, it was illegally stolen and republished in violation of US and international copyright & trademark laws. The legal version of this report can be viewed at https://ledgergazette.com/2017/12/15/ultragenyx-pharmaceutical-rare-downgraded-by-bidaskclub.html.

About Ultragenyx Pharmaceutical

Ultragenyx Pharmaceutical Inc is a clinical-stage biopharmaceutical company. The Company is focused on the identification, acquisition, development, and commercialization of products for the treatment of genetic diseases. Its clinical-stage pipeline consists of two product categories: biologics (including a monoclonal antibody and an enzyme replacement therapy), and small-molecule substrate replacement therapies.

Analyst Recommendations for Ultragenyx Pharmaceutical (NASDAQ:RARE)

Receive News & Ratings for Ultragenyx Pharmaceutical Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Ultragenyx Pharmaceutical and related companies with MarketBeat.com's FREE daily email newsletter.

Leave a Reply